Recent Updates
Recently added Catalysts
KAPA Positive Sentiment

Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Kairos Pharma has been awarded the 2026 Biotech Breakthrough Award in the Cancer Immunology category. The award recognizes its innovative work with ENV-105, which targets drug resistance in metastatic prostate cancer and non-small cell lung cancer. This acknowledgment highlights the company's commitment to advancing cancer treatment.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kairos Pharma won the 2026 Biotech Breakthrough Award.
  • Recognition for ENV-105's innovative approach.
  • Focus on drug resistance in cancer treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~5 mo
High dilution risk
Lead asset
Carotuximab
Phase 1 · Non Small Cell Lung Cancer

Full Press Release Details

LOS ANGELES--(BUSINESS WIRE)---- $KAPA--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for its work with ENV-105 targeting cancer drug resistance in metastatic prostate cancer and non-small cell lung cancer. Kairos Pharma was recognized for its differentiated approach to targeting the biologi

Frequently Asked Questions

What award did Kairos Pharma win?

Kairos Pharma won the 2026 Biotech Breakthrough Award.

What is ENV-105 targeting?

ENV-105 targets drug resistance in metastatic prostate cancer.

In which category was Kairos Pharma recognized?

They were recognized in the Cancer Immunology category.

What types of cancer does ENV-105 address?

ENV-105 addresses metastatic prostate cancer and non-small cell lung cancer.

ShareAdd on Google
Tags: KAPA Kairos Pharma ENV-105 biotech breakthrough cancer immunology drug resistance
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$3M liquidity · $0M/mo burn
~5 mo
High dilution risk
Lead asset
CarotuximabPhase 1
Non Small Cell Lung Cancer →